SHORT COURSES

PRE-CONFERENCE SHORT COURSES*
APRIL 26

(SC2) FRAGMENT-INSPIRED MEDICINAL CHEMISTRY
12:00 pm – 3:00 pm

Fragment-based approaches as platforms for medicinal chemistry
Fragment-based methods that inspire fresh approaches to lead generation
Optimization of fragment hits
Combining technology with fragment-based methods to advance medicinal chemistry
Facing the challenge of applying fragment-based approaches when structural information is not available
Promises and pitfalls of surface plasmon resonance (SPR) for fragment methods

Course Instructors:

Daniel A. Erlanson, Ph.D., Co-founder, Carmot Therapeutics, Inc.
Michelle Arkin, Ph.D., Associate Director, Biology, Small Molecule Discovery Center, Pharmaceutical Chemistry, University of California, San Francisco

View instructor biographies here

AGENDA:
12:00 pm Welcome and Introductions

12:15 Part 1: Concepts and Challenges
Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.

1:00 Part 2: How Do You Find Low-Affinity Fragments?
Michelle Arkin, Ph.D., Associate Director, Biology, Small Molecule Discovery Center, Pharmaceutical Chemistry, University of California, San Francisco

1:45 Refreshment Break

2:00 Part 3: What Can You Do with a Fragment?
Daniel A. Erlanson, Ph.D., Co-Founder, Carmot Therapeutics, Inc.

2:45 Group Discussion/Roundtable

3:00 End of Course

(SC3) ADVANCED TOOLS AND TECHNOLOGIES FOR FRAGMENT-BASED DESIGN
3:30 pm – 6:30 pm

Fragment Library Design
Fragment Library Screening
NMR Technology
SPR as a Tool for FBBD – benefits and challenges

AGENDA:

3:30 Welcome and Introduction

3:35 Novel Methods for Biosensor-based Fragment Screening

David G. Myszka, Ph.D., Director, Center for Biomolecular Interaction Analysis, University of Utah

4:30 Incorporating Elements of Natural Products into Fragment Based Drug Discovery

Andrea Altieri, Ph.D., Project Manager, ASINEX ltd

5:15 Refreshment Break

5:30 NMR Screening In FBDD: A Structural Tool in the Absence of Structure

Edward Zartler, Ph.D., Research Fellow, Merck

6:15 - 6:30 Discussion and Q&A with Speakers

*Separate Registration Required

(SC1) CHEMISTRY OUTSOURCING SYMPOSIUM
9:00 am – 5:00 pm

This full day event, preceding the start of the multi-track Drug Discovery Chemistry conference, uniquely gathers chemists and outsourcing managers from all work situations to share experiences and learn from each others challenges. With plenty of time for networking anchored by concrete topics and focused, moderated discussions, this symposium is designed to help small and large companies get the most from their outsourcing relationships.

Keynote:

Dinesh V. Patel, Ph.D., CEO and President, Protagonist Therapeutics

Faculty:

Hui Cai, Ph.D., M.B.A., Vice President, Business Development, WuXi AppTec Inc.
Qun (Max) Dang, Ph.D., Senior Investigator, XDPS, Merck & Co., Inc.
Bill Farley, Vice President, Business Development, ChemDiv
Omar Haffar, Ph.D., President, Presidio Pharmaceuticals
Scott Hecker, Ph.D., Vice President, Chemistry, Mpex Pharmaceuticals, Inc.
Rekha Hemarajani, M.B.A., Senior Director, Business Development, Exelixis
Leping Li, Ph.D., Vice President of Chemistry, Presidio Pharmaceuticals
Jay Lichter, Ph.D., CEO, Afraxis
James E. Macdonald, Ph.D., Chemistry Consultant, formerly Director of Chemistry, itherX Pharmaceuticals
Raju Mohan, Ph.D., Vice President, Chemistry, Exelixis
Michael Kolb, Ph.D., Vice President, Chemical Development, Pfizer/Wyeth Inc.
H. Michael Petrassi, Ph.D., Sr. Res. Investigator, Chemistry Outsourcing Liason, Novartis Research Foundation
Dean Wilson, Ph.D., Associate Director Chemistry, Vertex Pharmaceuticals Inc.
Nikolay Savchuk, Director, Torrey Pines Investment
Richard Soll, Ph.D., Senior Vice President of Integrated Services, WuXiApTech Inc.